Clinical Trials (PDQ®)
|Phase III||Biomarker/Laboratory analysis, Prevention||Closed||35 and over||Other||MAP3|
CAN-NCIC-MAP3, PFIZER-EXEAPO-0028-150, ExCel, CDR0000363802, NCT00083174
RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen. This study was analyzed in April 2011 and showed a 65% reduction in the incidence of invasive breast cancer in women receiving exemestane compared to women on placebo.
PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is to allow all study participants the opportunity to complete 5 years of exemestane.
Further Study Information
Previously: To determine if exemestane reduces the incidence of invasive breast cancer compared with placebo.
Currently: To determine the frequency of serious adverse events for post-menopausal women at high-risk of developing breast cancer who choose to receive 5 years of exemestane as preventative therapy.
Previously: (same as is currently listed in PDQ) Currently: To address the Trial Committee and Sponsor's commitment to allow women who are randomized to the MAP.3 trial to receive 5 years of exemestane therapy.
OUTLINE: This study was a randomized, double-blind, placebo-controlled, multicentre study. Protocol-specified analyses were performed in April 2011. The results of these analyses are posted in the Results section. Following the amendment of May 2011, the study is now open-label and all eligible patients are receiving exemestane from participating sites for a total of 5 years. After exemestane is stopped, there is no further follow-up.
PROJECTED ACCRUAL:There were 4560 women from the United States, Canada, Spain and France who took part in this study.
- At increased risk of developing breast cancer, due to at least one of the following risk factors:
- Gail score ≥ 1.66
- Age ≥ 60 years
- Prior atypical ductal hyperplasia, lobular hyperplasia, or lobular carcinoma in situ on breast biopsy
- Prior ductal carcinoma in situ (DCIS) treated with total mastectomy with or without tamoxifen (tamoxifen must have been completed ≥ 3 months prior to randomization)
- No prior DCIS treated with lumpectomy with or without radiation
- No prior invasive breast cancer
- Not BRCA1 or BRCA2 carriers
- 35 and over
- Postmenopausal, defined as one of the following:
- over 50 years of age with no spontaneous menses for at least 12 months before study entry
- 50 years of age or under with no menses (spontaneous or secondary to hysterectomy) for at least 12 months before study entry AND with follicle-stimulating hormone level within postmenopausal range
- Underwent prior bilateral oophorectomy
- No other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumors with no evidence of disease for ≥ 5 years
- No uncontrolled hypothyroidism or hyperthyroidism
- No major medical or psychiatric illness (including substance and alcohol abuse within the past 2 years) that would preclude study participation or compliance
- Must be accessible for treatment and follow-up
- Willing to complete quality of life questionnaires in either English or French
Current: MAP.3 participants who were randomized to the exemestane arm, are currently receiving exemestane as part of the MAP.3 study and who have not completed 5 years of exemestane.
OR MAP.3 study participants who were randomized to the placebo arm and who have either completed 5 years of study drug or who are still receiving placebo. Note: this applies only to centres that choose to allow placebo "cross-over".
PRIOR CONCURRENT THERAPY:
- More than 3 months since prior and no concurrent hormone replacement therapies
- More than 3 months since systemic estrogenic, androgenic, or progestational agents
- More than 3 months since prior and no concurrent hormonal therapies, including, but not limited to the following:
- Luteinizing-hormone releasing-hormone analogs (e.g., goserelin or leuprolide)
- Progestogens (e.g., megestrol)
- Prolactin inhibitors (e.g., bromocriptine)
- Antiandrogens (e.g., cyproterone acetate)
- Selective estrogen-receptor modulators (e.g., tamoxifen, toremifene, or raloxifene)
- No investigational drug within 30 days or 5 half lives prior to randomization
- No concurrent endocrine therapy
- No concurrent estrogens, androgens, or progesterones
- Concurrent low dose (≤ 100 mg/day) prophylactic aspirin allowed
- Concurrent bisphosphonates for prevention or treatment of osteoporosis allowed
- No other concurrent medications that may have an effect on study endpoints
Current: There are no prior concurrent therapy restrictions for the amended MAP.3 study.
Trial Lead Organizations/Sponsors
NCIC-Clinical Trials GroupGrupo Espanol de Investigacion del Cancer de Mama
Federation Nationale des Centres de Lutte Contre le Cancer
|Paul Edward Goss||Study Chair|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00083174
ClinicalTrials.gov processed this data on January 22, 2015
Back to Top